Blinatumomab in acute lymphoblastic leukemia treatment: features of therapy organization, supplement issues and therapy-related toxicity. Literature review and own experience
https://doi.org/10.21682/2311-1267-2021-8-4-39-46
Abstract
Acute lymphoblastic leukemia is the most common tumor of childhood. Using of modern treatment chemotherapy regimens, we can reach about 90 % of 5-year survival. An important problem – patients with relapses of the disease, as well as children with the persistence of minimal residual disease (MRD), which is absolutely necessary in hematopoietic stem cell transplantation aspects. The possibilities of continuous intensive chemotherapy are limited by high toxicity, and therefore targeted drugs are used to achieve MRD-negative remission in children, in particular, a bispecific antibody – blinatumomab.
This article presents our own experience of using blinatumomab in patients using various financial sources, the technical features of using within the federal medical center. Also, undesirable effects of the drug and their therapy are mentioned.
About the Authors
N. A. BatmanovaRussian Federation
N.A. Batmanova: Cand. of Sci. (Med.), Head of the Department of Pediatric Oncology and Hematology (Chemotherapy of Hemoblastosis) No. 2 of the Research Institute of Pediatric Oncology and Hematology
115478, Moscow, Kashirskoe Shosse, 23
T. T. Valiev
Russian Federation
T.T. Valiev: Dr. of Sci. (Med.), Head of the Department of Pediatric Oncology and Hematology (Chemotherapy of Hemoblastosis) No. 1 of the Research Institute of Pediatric Oncology and Hematology
115478, Moscow, Kashirskoe Shosse, 23
K. I. Kirgizov
Russian Federation
K.I. Kirgizov: Cand. of Sci. (Med.), Deputy Director for Scientific and Educational Work of Research Institute of Pediatric Oncology and Hematology
115478, Moscow, Kashirskoe Shosse, 23
S. R. Varfolomeeva
Russian Federation
S.R. Varfolomeeva: Dr. of Sci. (Med.), Professor, Director of the Research Institute of Pediatric Oncology and Hematology
115478, Moscow, Kashirskoe Shosse, 23
References
1. Pui C.H., Nichols K.E., Yang J.J. Somatic and germline genomics in pediatric acute lymphoblastic leukaemia. Nat Rev Clin Oncol. 2019;16(4):227–40. doi:10.1038/s41571-018-0136-6.
2. Jeha S., Pei D., Choi J., Cheng C., Sandlund J.T., Coustan-Smith E., Campana D., Inaba H., Rubnitz J.E., Ribeiro R.C., Gruber T.A., Raimondi S.C., Khan R.B., Yang J.J., Mullighan C.G., Downing J.R., Evans W.E., Relling M.V., Pui C.-H. Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. J Clin Oncol. 2019;37(35):3377–91. doi:10.1200/JCO.19.01692.
3. Benjamin J.E., Stein A.S. The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia. Ther Adv Hematol. 2016;7(3);142–56. doi:10.1177/2040620716640422.
4. Locatelly F., Whitlock J., Peters C., Chen-Santel C., Chia V., Dennis R.M., Heym K.M., Katz A.J., Kelsh M.A., Sposto R., Tu H., Tuglus C.A., Verma A., Vinti L., Wilkes J.J., Zubarovskaja N., Zugmaier G., von Stackelberg A., Sun W. Blinatumomab versus historical standard therapy in pediatric patients with relapsed/ refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. Leukemia. 2020;34(9):2473–8. doi:10.1038/s41375-020-0770-8.
5. Hoffman L.M., Gore L. Blinatumomab, a bi-specific anti-CD 19/CD3 BiTE® antibody for the treatment of acute lymphoblastic leukemia: perspectives and current pediatric applications. Front Oncol. 2014;4:63. doi:10.3389/fonc.2014.00063.
6. Nagorsen D., Kufer P., Baeuerle P.A., Bargou R. Blinatumomab: a historical perspective. Pharmacol Ther. 2012;136(3):334–42. doi:10.1016/j.pharmthera.2012.07.013.
7. von Stackelberg A., Locatelli F., Zugmaier G., Handgretinger R., Trippett T.M., Rizzari C., Bader P., OʼBrien M.M., Brethon B., Bhojwani D., Schlegel P.G., Borkhardt A., Rheingold S.R., Cooper T.M., Zwaan C.M., Barnette P., Messina C., Michel G., DuBois S.G., Hu K., Zhu M., Whitlock J.A., Gore L. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/ Refractory Acute Lymphoblastic Leukemia. J Clin Oncol. 2016;34(36):4381–9. doi:10.1200/JCO.2016.67.3301.
8. Gokbuget N., Zugmaier G., Klinger M., Kufer P., Stelljes M., Viardot A., Horst H.A., Neumann S., Brüggemann M., Ottmann O.G., Burmeister T., Wessiepe D., Topp M.S., Bargou R. Long-term relapsefree survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia. Haematologica. 2017;102(4):e132–5. doi:10.3324/haematol.2016.153957.
9. Jasinski S., De Los Reyes F., Yametti G.C., Pierro J., Raetz E., Caroll W.L. Immunotherapy in pediatric B-acute lymphoblastic leukemia: Advances and ongoing challenges. Paediatr Drugs. 2020;22(5):485–99. doi:10.1007/s40272-020-00413-3.
10. Achtari M., Kum-Ja Lee, Weissman A., Tulpule S., Aldoss I., Akhtari M. Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults. Ther Clin Risk Manag. 2016;12:1301–10. doi:10.2147/TCRM.S84261.
11. Queudeville M., Ebiger M. Blinatumomab in pediatric acute lymphoblastic leukemia – from salvage to first line therapy (a systematic review). J Clin Med. 2021;10(12):2544. doi:10.3390/jcm10122544.
12. Jain T., Litzow M.R. No free rides: management of toxicities of novel immunotherapies in ALL, including financial. Hematology Am Soc Hematol Educ Program. 2018;2018(1):25–34. doi:10.1182/asheducation-2018.1.25.
13. Inaba H., Pui C.-H. Immunotherapy in pediatric acute lymphoblastic leukemia. Cancer Metastasis Rev. 2019;38(4):595–610. doi:10.1007/s10555-019-09834-0
14. Shuvaev V.A., Ushakova O.V., Mullo E.I., Tolstykh T.V., Triputen N.Z. Use of Blinatumomab in Acute Lymphoblastic Leukemia in Municipal Healthcare: A Case Report. Klinicheskaya onkogematologiya = Clinical Oncohematology. 2021;14(2):198–203. (In Russ.). doi:10.21320/2500-2139-2021-14-2-198-203.
15. Bondarenko S.N., Parovichnikova E.N., Maschan A.A., Baranova O.Yu., Shelekhova T.V., Doronin V.A., Mel’nichenko V.Ya., Kaplanov K.D., Uspenskaya O.S., Sokolov A.N., Myakova N.V., Moiseev I.S., Markova I.V., Darskaya E.I., Smirnova A.G., Bykova T.A., Ayubova B.I., Samorodova I.A., Babenko E.V., Barkhatov I.M., Gindina T.L., Kulagin A.D., Afanas’ev B.V. Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Russian Multicenter Clinical Trial. Klinicheskaya onkogematologiya = Clinical Oncohematology. 2019;12(2):145–53. (In Russ.). doi:10.21320/2500-2139-2019-12-2-145-153
16. Fuster J.L., Bautista F., Gonzales B., Fernamdez J.M., Rives S., Dapena J.L., Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP). Blinatumomab to improve the outcome of children with relapsed B-cell acute lymphoblastic leukemia. Clin Transl Oncol. 2021;23(9):1963–6. doi:10.1007/s12094-021-02590-0.
17. Locatelli F., Zugmaier G., Merger N., Bader P., Jeha S., Schlegel P., Bourquin J.-P., Handgretinger R., Brethon B., Rossig C., Chen-Santel C. Blinatumomab in pediatric patients with relapsed/ refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study. Blood Cancer J. 2020;10(7):77. doi:10.1038/s41408-020-00342-x.
Review
For citations:
Batmanova N.A., Valiev T.T., Kirgizov K.I., Varfolomeeva S.R. Blinatumomab in acute lymphoblastic leukemia treatment: features of therapy organization, supplement issues and therapy-related toxicity. Literature review and own experience. Russian Journal of Pediatric Hematology and Oncology. 2021;8(4):39-46. (In Russ.) https://doi.org/10.21682/2311-1267-2021-8-4-39-46